Clinical results from the UK Optimum/Muknine Trial
Latest results from the UK Optimum Trial are presented by Dr. Martin F. Kaiser, UK, in this MEDtalk. Findings suggest patients with diagnosed multiple myeloma (NDMM) and patients with primary plasma cell leukemia (pPCL), to benefit significantly in progression free survival at 18 months when treated in OPTIMUM (5-drug combination (Dara-CVRd) followed by stem cell transplantation and 4-drug combination (Dara-VRd)), compared a digital comparator arm using molecularly matched patients from another study (NCRI Myeloma XI/XI+ trial (NCT01554852)).
For more details read abstract: https://ash.confex.com/ash/2021/webprogram/Paper144990.html
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.